DiRaimondo Thomas 4
4 · Janux Therapeutics, Inc. · Filed Sep 27, 2024
Insider Transaction Report
Form 4
DiRaimondo Thomas
Chief Scientific Officer
Transactions
- Sale
Common Stock
2024-09-27$47.22/sh−675$31,877→ 97,938 total - Sale
Common Stock
2024-09-27$46.21/sh−4,325$199,840→ 98,613 total
Footnotes (4)
- [F1]The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 28, 2024.
- [F2]The weighted average sale price for the transaction reported was $46.2057 and the range of prices were between $45.70 and $46.69. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- [F3]Includes 1,406 shares acquired under the Issuer's 2021 Employee Stock Purchase Plan on May 15, 2024.
- [F4]The weighted average sale price for the transaction reported was $47.2245 and the range of prices were between $46.79 and $47.77. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.